FULC Stock Analysis: Fulcrum Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 243m USD | 12M Return: -46.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.0M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fulcrum Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined diseases with high unmet medical need. As a clinical-stage company, it has no approved or revenue-generating products and depends on capital markets and partnerships to fund its research and development activities. The company is listed on NASDAQ under the ticker FULC and falls within the Health Care sectors Pharmaceuticals sub-industry.
Its lead clinical candidate is pociredir, a fetal hemoglobin inducer currently in a Phase 1b trial for sickle cell disease and beta-thalassemia. Beyond pociredir, the company is pursuing early-stage discovery work in diamond-blackfan anemia, bone marrow failure syndromes, additional fetal hemoglobin inducers, and fibrotic disorders. Fulcrum also holds a license agreement with CAMP4 covering certain small-molecule compounds and associated intellectual property for research, development, and commercialization.
Fulcrum Therapeutics was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. The company completed its initial public offering in July 2019 and is classified as a micro-cap stock.
- Pociredir Phase 1b sickle cell data readout expected
- Cash burn rate raises runway concerns
- CAMP4 licensing deal adds development milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA -21.54 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.18 > 3% & CFO -63.6m > Net Income -76.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 34.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (76.2m) vs 12m ago 21.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 32.97%; Δ -32.97% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.95 (Total Current Assets 338.7m - Total Current Liabilities 9.86m) / Total Assets 346.8m |
| B: -1.77 (Retained Earnings -613.2m / Total Assets 346.8m) |
| C: -0.26 (EBIT TTM -76.1m / Avg Total Assets 294.7m) |
| D: 24.75 (Book Value of Equity 333.3m / Total Liabilities 13.5m) |
| Altman-Z'' = 24.71 = AAA |
As of July 08, 2026, the stock is trading at USD 3.77 with a total of 2,751,781 shares traded. Over the past week, the price has changed by +1.07%, over one month by +9.59%, over three months by -51.85% and over the past year by -46.30%.
Current recommended Stop Loss: 3.40 (which is 9.8% or 1.2 ATR below the current price).
Fulcrum Therapeutics has received a consensus analysts rating of 3.57. Therefore, it is recommended to hold FULC.
- StrongBuy: 2
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 5.4 | 44% |
P/S = 2.6567
P/B = 0.7287
Revenue TTM = 0.0 USD
EBIT TTM = -76.1m USD
EBITDA TTM = -74.7m USD
Long Term Debt = 3.41m USD (estimated: total debt 5.87m - short term 2.46m)
Short Term Debt = 2.46m USD (from shortTermDebt, last quarter)
Debt = 5.87m USD (from shortLongTermDebtTotal, last quarter) (leases 5.87m already included)
Net Debt = -327.4m USD (calculated: Debt 5.87m - CCE 333.3m)
Enterprise Value = 242.5m USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = unknown (Ebit TTM -76.1m / Interest Expense TTM 0.0)
EV/FCF = -3.80x (Enterprise Value 242.5m / FCF TTM -63.9m)
FCF Yield = -26.34% (FCF TTM -63.9m / Enterprise Value 242.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.39m) / Revenue TTM)
Tobins Q-Ratio = 0.70 (Enterprise Value 242.5m / Total Assets 346.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.87m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -60.1m (EBIT -76.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 34.33 (Total Current Assets 338.7m / Total Current Liabilities 9.86m)
Debt / Equity = 0.02 (Debt 5.87m / totalStockholderEquity, last quarter 333.3m)
Debt / EBITDA = 4.38 (negative EBITDA) (Net Debt -327.4m / EBITDA -74.7m)
Debt / FCF = 5.13 (negative FCF - burning cash) (Net Debt -327.4m / FCF TTM -63.9m)
Total Stockholder Equity = 273.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -25.83% (Net Income -76.1m / Total Assets 346.8m)
RoE = -27.80% (Net Income TTM -76.1m / Total Stockholder Equity 273.8m)
RoCE = -27.46% (EBIT -76.1m / Capital Employed (Equity 273.8m + L.T.Debt 3.41m))
RoIC = -17.72% (negative operating profit) (NOPAT -60.1m / Invested Capital 339.4m)
WACC = 8.91% (E(242.5m)/V(248.4m) * Re(9.13%) + D(5.87m)/V(248.4m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.0 | Cagr: 9.71%
[DCF] Fair Price = unknown (Cash Flow -63.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.17 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.23 | Chg30d=+18.84% | Revisions=+57% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+46.10% | Revisions=+70% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.80 | Chg30d=+31.99% | Revisions=+70% | GrowthEPS=+32.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.63 | Chg30d=+52.81% | Revisions=+70% | GrowthEPS=+21.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +89% (up=25, down=0)